Eslicarbazepine acetate (Neuropathic Pain) - Forecast and Market Analysis to 2022
Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.
Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/eslicarbazepine-acetate-neuropathic-pain-forecast-and-market-analysis-to-2022
New treatments will target some key unmet needs in terms of efficacy and tolerability, but opportunities will remain for drugs that can more reliably eradicated NP in targeted patient populations, as well as offering an improved safety profile.
Eslicarbazepine acetate is a drug that was developed by Bial-Portela & Ca., and is currently in Phase III of clinical development for PDN and PHN. It has already been approved for marketing in Europe and the US for the adjunctive treatment of adults with partial epileptic seizures. It was launched in the EU by Bial in conjunction with Eisai in 2009, and received FDA approval in the US in November 2013, where it is being developed and commercialized by Sunovion Pharmaceuticals under the brand name Aptiom.